SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

Kalaris Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.0001 per value

(Title of Class of Securities)

482929106

(CUSIP Number)

03/18/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

482929106

Names of Reporting Persons

GILEAD SCIENCES, INC.

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 723,273.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 723,273.00
8	Shared Dispositive Power 0.00

Aggregate Amount Beneficially Owned by Each Reporting Person

723,273.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

3.9 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: Percentage based on 18,702,413 shares of Common Stock outstanding immediately following the effective time (the "Effective Time") of the merger, pursuant to the terms of the Agreement and Plan of Merger, dated as of November 7, 2024, by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer ("Merger Sub"), and Kalaris Tx, Inc. (formerly Kalaris Therapeutics, Inc.), a Delaware corporation ("Legacy Kalaris"), of Merger Sub with and into Legacy Kalaris, with Legacy Kalaris continuing as a wholly owned subsidiary of the Issuer, as disclosed in the Issuer's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on March 18, 2025. Immediately following the Effective Time, the Issuer changed its name to "Kalaris Therapeutics, Inc." The Common Stock, which was previously listed on The Nasdaq Capital Market and traded under the ticker symbol "ALVR" through the close of business on March 18, 2025, commenced trading on The Nasdaq Global Market under the ticker symbol "KLRS" on March 19, 2025, and is represented by the new CUSIP number above.

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

Kalaris Therapeutics, Inc.

(b)

Address of issuer's principal executive offices:

628 Middlefield Road, Palo Alto, California, 94301

Item 2.

(a)

Name of person filing:

Gilead Sciences, Inc.

(b)

Address or principal business office or, if none, residence:

333 Lakeside Drive Foster City, California 94404

(c)

Citizenship:

Delaware

(d)

Title of class of securities:

Common Stock, $0.0001 per value

(e)

CUSIP No.:

482929106

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

723,273

(b)

Percent of class:

3.9 %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

723,273

(ii) Shared power to vote or to direct the vote:

(iii) Sole power to dispose or to direct the disposition of:

723,273

(iv) Shared power to dispose or to direct the disposition of:

Item 5.

Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

GILEAD SCIENCES, INC.

Signature:	/s/ Andrew D. Dickinson
Name/Title:	Andrew D. Dickinson, Executive Vice President and Chief Financial Officer
Date:	03/20/2025

Amendment: SEC Form SCHEDULE 13G/A filed by AlloVir Inc.